A novel target for development of a new T-cell specific immunosuppresant

CaMKIV plays an important role in T cell activation and is an important target for immunosuppressive agents. The present invention relates to Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) and, in particular, to methods of screening compounds for their ability to act as CaMKIV agonists or antagonists. The invention further relates to compounds identified using such methods and to therapeutic methodologies based on same. Agents identified using the screen provided there are T cell specific and thus substantially free of adverse side effects.

Duke File (IDF) Number

T-001381

Inventor(s)

  • Means, Anthony
  • Anderson, Kristin
  • Ribar, Thomas

Patents

    • Patent Number: 7,105,312
    • Title: CA2+/Calmodulin-Dependent Protein Kinase IV
    • Country: United States of America

For more information please contact

College

School of Medicine (SOM)